Clx-0921

Clx-0921

SCHEMBL3794540

COC(=O)C(=Cc1cc(OC)cc(OC)c1)c1ccc(Oc2ccc(CC3SC(=O)NC3=O)cc2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PPARG

The experimentally established mechanism targets of Clx-0921. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG known ✓ P37231 9/20 1.00
MPC2 O95563 1/20 0.52
CYP2C8 P10632 1/20 0.52
CYP2C9 P11712 1/20 0.52
FFAR1 O14842 5/20 0.49
PPARA Q07869 4/20 0.45
CA2 P00918 1/20 0.45
MAPT P10636 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
RAB9A P51151 1/20 0.44
PTPN1 P18031 1/20 0.42
ALDH1A1 P00352 1/20 0.42
TP53 P04637 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clx-0921 SCHEMBL3794534 1.00 PPARG (1.00) PPARGMPC2CYP2C8CYP2C9FFAR1
Clx-0921 SCHEMBL3798951 1.00 PPARG (1.00) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL6827386 0.93 PPARG (0.88) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL12631345 0.93 PPARG (0.86) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL4434728 0.91 PPARG (0.84) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL4434725 0.91 PPARG (0.84) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL3792635 0.91 PPARG (0.83) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL3792638 0.91 PPARG (0.83) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL3798936 0.91 PPARG (0.83) PPARGMPC2CYP2C8CYP2C9FFAR1
SCHEMBL3798938 0.91 PPARG (0.83) PPARGMPC2CYP2C8CYP2C9FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718682-B2 Heterocyclic analogs of diphenylethylene compounds THERACOS, INC. (US) 2010-05-18 US claimed
US-7105552-B2 Heterocyclic analogs of diphenylethylene compounds THERACOS, INC. (US) 2006-09-12 US claimed
EP-1007039-B1 NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS CALYX THERAPEUTICS INC (US) 2004-03-03 EP claimed
EP-1360178-A2 NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS Calyx Therapeutics, Inc. (US) 2003-11-12 EP claimed
US-20030181494-A1 Novel heterocyclic analogs of diphenylethylene compounds SEED, BRIAN 2003-09-25 US claimed
US-20020032225-A1 Novel heterocyclic analogs of diphenylethylene compounds SEED, BRIAN 2002-03-14 US claimed
US-20020025975-A1 Novel Heterocyclic analogs of diphenylethylene compounds CALYX THERAPEUTICS, INC. 2002-02-28 US claimed
WO-2001095859-A2 NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS CALYX THERAPEUTICS, INC. (US) 2001-12-20 WO claimed
US-6331633-B1 ANTIDIABETIC AGENTS WITH NO LIVER TOXICITY CALYX THERAPEUTICS INC. 2001-12-18 US claimed
CN-112209896-B Thiazolidinedione derivatives and pharmaceutical compositions containing the same 苏州泽璟生物制药股份有限公司 2023-05-16 CN disclosed
US-7718682-B2 Heterocyclic analogs of diphenylethylene compounds THERACOS, INC. (US) 2010-05-18 US disclosed
EP-1360178-B1 NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS THERACOS INC (US) 2009-02-18 EP disclosed
US-20080293949-A1 Novel heterocyclic analogs of diphenylethylene compounds THERACOS, INC. (US) 2008-11-27 US disclosed
EP-1625207-A4 COMPOUNDS FOR TREATMENT OF INFLAMMATION, DIABETES AND RELATED DISORDERS THERACOS INC (US) 2008-11-12 EP disclosed
WO-2004033438-A1 NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS THERACOS, INC. (US) 2004-04-22 WO disclosed
EP-1360178-A2 NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS Calyx Therapeutics, Inc. (US) 2003-11-12 EP disclosed
US-20030181494-A1 Novel heterocyclic analogs of diphenylethylene compounds SEED, BRIAN 2003-09-25 US disclosed
US-20020032225-A1 Novel heterocyclic analogs of diphenylethylene compounds SEED, BRIAN 2002-03-14 US disclosed
US-20020025975-A1 Novel Heterocyclic analogs of diphenylethylene compounds CALYX THERAPEUTICS, INC. 2002-02-28 US disclosed
WO-2001095859-A2 NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS CALYX THERAPEUTICS, INC. (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020025975-A1 Novel Heterocyclic analogs of diphenylethylene compounds FFAR2, GPR119, FFAR4 PPARG 25/4885MPC2 126/4885CYP2C8 2373/4885
US-20020032225-A1 Novel heterocyclic analogs of diphenylethylene compounds FFAR2, GPR119, FFAR4 PPARG 25/4885MPC2 154/4885CYP2C8 2246/4885
US-20030181494-A1 Novel heterocyclic analogs of diphenylethylene compounds FFAR2, FFAR4, GPR119 PPARG 10/4885MPC2 753/4885CYP2C8 1831/4885
US-20080293949-A1 Novel heterocyclic analogs of diphenylethylene compounds FFAR2, FFAR4, GPR119 PPARG 10/4885MPC2 753/4885CYP2C8 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.